Promotor Hypomethylation Mediated Upregulation of VCAN Targets Twist1 to Promote EndMT in Hypoxia-Induced Pulmonary Hypertension.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE

Original Publication: Oxford : Wiley-Blackwell

Twist-Related Protein 1*/metabolism ; Twist-Related Protein 1*/genetics ; DNA Methylation* ; Hypoxia*/metabolism ; Hypoxia*/complications ; Versicans*/metabolism ; Versicans*/genetics ; Promoter Regions, Genetic* ; Hypertension, Pulmonary*/metabolism ; Hypertension, Pulmonary*/genetics ; Hypertension, Pulmonary*/etiology ; Hypertension, Pulmonary*/physiopathology ; Up-Regulation* ; Disease Models, Animal* ; Nuclear Proteins*/genetics ; Nuclear Proteins*/metabolism ; Epithelial-Mesenchymal Transition*/genetics; Animals ; Humans ; Male ; Pulmonary Artery/metabolism ; Pulmonary Artery/pathology ; Mice, Inbred C57BL ; Vascular Remodeling ; Mice ; Cells, Cultured ; Endothelial Cells/metabolism ; Female ; Endothelial-Mesenchymal Transition

Background: Hypoxia-induced pulmonary hypertension (HPH) is a severe vascular disorder that is characterized by the involvement of endothelial-to-mesenchymal transition (EndMT) in its pathogenesis. Our previous research has suggested that the gene versican may have a crucial role in the development of HPH. However, the exact function of versican in HPH requires further investigation.
Methods and Results: The expression of versican and markers of EndMT was assessed using Western blot, immunohistochemistry, and immunofluorescence. Vascular remodeling and right ventricular hypertrophy in patients with HPH and mice were evaluated through hematoxylin and eosin staining, Masson's staining, and hemodynamic measurements. Protein interactions were validated using co-immunoprecipitation, and the DNA methylation level of versican was examined using methylation-specific polymerase chain reaction. Compared with the control, EndMT was observed in patients with HPH, HPH mouse models, and hypoxia-treated human pulmonary artery endothelial cells, accompanied by a significant increase of versican. Endothelium-specific knockdown of versican reversed HPH progression and effectively prevented EndMT in mouse models and human pulmonary artery endothelial cells. We further confirmed that versican participated in EndMT by targeting the key transcription factor Twist1. Additionally, the upregulation of versican may be attributed to promoter hypomethylation, which was mediated by reduced DNA methyltransferases activity under hypoxic conditions.
Conclusions: This study provides the initial evidence showcasing the role of promoter hypomethylation-mediated versican upregulation in promoting EndMT by targeting Twist1, which facilitates vascular remodeling and the progression of HPH. These findings offer a promising new target for the treatment of HPH.

Matrix Biol. 2021 Mar;97:40-57. (PMID: 33454424)
J Heart Lung Transplant. 2019 Feb;38(2):145-155. (PMID: 30391191)
Cells. 2022 Jun 03;11(11):. (PMID: 35681530)
Biomolecules. 2017 Jan 05;7(1):. (PMID: 28067760)
Glycobiology. 2015 Mar;25(3):243-51. (PMID: 25371494)
Int J Mol Med. 2018 Jul;42(1):270-278. (PMID: 29568878)
FEBS J. 2021 Dec;288(24):6850-6912. (PMID: 33605520)
Expert Rev Respir Med. 2022 May;16(5):519-528. (PMID: 35673969)
Hypertension. 2019 Oct;74(4):733-739. (PMID: 31476913)
Matrix Biol. 2018 Oct;71-72:396-420. (PMID: 29499356)
Oncotarget. 2017 May 19;8(32):52995-53016. (PMID: 28881789)
Eur Heart J. 2022 Oct 11;43(38):3618-3731. (PMID: 36017548)
Front Immunol. 2023 May 05;14:1162556. (PMID: 37215139)
Biomedicines. 2022 Jan 13;10(1):. (PMID: 35052850)
Cardiol Clin. 2020 May;38(2):243-255. (PMID: 32284101)
Genome Biol. 2021 Apr 30;22(1):127. (PMID: 33931130)
Int J Mol Sci. 2023 Apr 19;24(8):. (PMID: 37108649)
Sci Rep. 2019 Oct 8;9(1):14409. (PMID: 31595000)
Biol Reprod. 2017 Feb 1;96(2):424-434. (PMID: 28203702)
Clin Epigenetics. 2017 Apr 14;9:38. (PMID: 28416970)
Physiol Rev. 2019 Apr 1;99(2):1281-1324. (PMID: 30864875)
Methods. 2021 Mar;187:28-43. (PMID: 33039572)
Biomedicines. 2020 Dec 21;8(12):. (PMID: 33371458)
FEBS J. 2019 Aug;286(15):2830-2869. (PMID: 30908868)
Am J Respir Cell Mol Biol. 2018 Feb;58(2):194-207. (PMID: 28915063)
Int J Chron Obstruct Pulmon Dis. 2023 Nov 07;18:2457-2471. (PMID: 37955024)
J Histochem Cytochem. 2020 Nov;68(11):763-775. (PMID: 33131383)
Compr Physiol. 2023 Jan 30;13(1):4295-4319. (PMID: 36715285)
Adv Exp Med Biol. 2022;1389:111-136. (PMID: 36350508)
BMJ Med. 2023 Mar 23;2(1):e000137. (PMID: 37051026)
Eur Respir J. 2019 Jan 24;53(1):. (PMID: 30545970)
Antioxid Redox Signal. 2021 Apr 20;34(12):891-914. (PMID: 32746619)
Sci Adv. 2020 Dec 9;6(50):. (PMID: 33298433)
Vasc Health Risk Manag. 2023 Mar 03;19:103-126. (PMID: 36895278)
Mayo Clin Proc. 2020 Sep;95(9):1978-1988. (PMID: 32861339)
ERJ Open Res. 2023 Apr 17;9(2):. (PMID: 37077555)
Cells. 2020 Jan 06;9(1):. (PMID: 31935962)
Life Sci. 2023 Sep 1;328:121879. (PMID: 37355224)
J Cancer. 2019 Oct 21;10(26):6570-6583. (PMID: 31777586)
Cell Death Dis. 2019 Nov 27;10(12):899. (PMID: 31776330)
Cell Death Differ. 2019 Mar;26(3):565-579. (PMID: 29955124)
Cell Cycle. 2021 Aug;20(15):1477-1486. (PMID: 34266366)
Am J Physiol Lung Cell Mol Physiol. 2017 Dec 1;313(6):L1096-L1100. (PMID: 28839104)

Keywords: DNA methylation; Twist1; endothelial‐to‐mesenchymal transition; hypoxia‐induced pulmonary hypertension; versican

0 (Twist-Related Protein 1)
126968-45-4 (Versicans)
0 (TWIST1 protein, human)
0 (Nuclear Proteins)
0 (VCAN protein, human)
136253-27-5 (Twist1 protein, mouse)

Date Created: 20241122 Date Completed: 20241203 Latest Revision: 20250104

20250114

PMC11681555

10.1161/JAHA.124.036969

39578365